JAK2 and myeloproliferative neoplasm: Even though this echoes already known distinctive clinical features of MPN-SVT patients such as female sex and younger age, a recent study from the framework of the ERNEST registry project sheds light on the potential interaction of increased thrombotic risk in JAK2-V617F-positive PMF patients with lower IPSS scores [71].